ArticleBMC oral health2026
Orofacial tumours and tumour-like lesions: a 10-year retrospective study in a Nigerian tertiary hospital.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOrofacial tumours and tumour-like lesions encompass a diverse spectrum of benign and malignant conditions. Understanding their demographic distribution is essential for early diagnosis and optimal treatment planning. This study aimed to evaluate the prevalence and histopathological spectrum of OT/TLL in a Nigerian tertiary hospital and to compare findings with reports from other regions of the country.
methodsHistopathology records of all orofacial lesions diagnosed between January 2015 and December 2024 were reviewed. Data on demographics, anatomical sites, and histological diagnoses were analyzed. Lesions were categorized as benign or malignant and Chi-square tests, logistic regression, and odds ratios were calculated using SPSS version 26.
resultsA total of 588 patients were studied. Benign lesions predominated (84.0%) and reactive follicular hyperplasia was the most common diagnosis (47.0%) peaking in childhood. Ameloblastoma (8.6%) was the leading benign odontogenic neoplasm, especially in the 10-19 age group. Malignancy rates increased progressively by odds of 9.6% with each additional year of age (OR = 1.096, 95% CI: 1.067-1.126, p < 0.001). Squamous cell carcinoma (59.6%) as the most frequent with 73.2% of cases occurring in patients aged ≥ 50 years (χ²=112.4, p < 0.0001). Benign tumours showed a slight female predominance, whereas males had significantly higher malignancy rates than females (χ²=7.82, p = 0.005) and independently conferred 86% higher odds (OR = 1.86, 95% CI: 1.16-2.98, p = 0.010). The mandible was the main site for ameloblastoma, while SCC often involved the larynx and nasopharynx.
conclusionBenign orofacial lesions are highly prevalent, with reactive follicular hyperplasia being most common. Ameloblastoma and SCC represent the most significant benign and malignant neoplasms, respectively with age and male gender independent predictors of malignancy. These findings highlight the need for improved diagnostic services, oral health interventions, and strengthened cancer screening programs for early detection at high-risk sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.